London, UK, 11 Dec 2025, ZEX PR WIRE, Stelios Tzellos, Ph.D., is a UK-based molecular biologist and pharmaceutical analyst whose work has contributed to the understanding of both viral gene regulation and oncology market dynamics. With academic roots in biochemistry and molecular biology, and an industry career spanning consulting and analytics roles, Dr. Tzellos has become known for his involvement in evidence-driven oncology strategy.

After earning his Bachelor’s and Master’s degrees in Biochemistry at Imperial College London, he completed a doctorate in Molecular Biology at the same institution. His Ph.D. research explored the differential regulatory effects of EBV EBNA-2 proteins on host and viral genes. The focus of this work was on understanding how a single amino acid substitution (S442D) in the EBNA-2 protein alters its ability to induce genes like CXCR7, contributing to the growth-promoting phenotype seen in Type 1 EBV.

Dr. Tzellos’ first-author publication, as well as co-authored papers from this research, are indexed in PubMed and remain relevant to those studying EBV biology, B-cell transformation, and transcriptional regulation.

Following completion of his Ph.D., Dr. Tzellos moved into pharmaceutical market analysis, beginning at GlobalData. There, as an Oncology and Haematology Analyst, he participated in market forecasting and treatment landscape evaluations. He was quoted in a 2014 industry report focused on the projected growth of the Hodgkin’s lymphoma treatment market. His comments highlighted the significance of Adcetris in reshaping access for premium-priced therapies targeting R/R disease subsets:

“Adcetris currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period. Premium-priced pipeline therapies that target the R/R Hodgkin’s lymphoma population will find it easier to penetrate the market, as Adcetris has already opened the door for expensive therapeutics in this setting.”

That statement has since been cited in discussions about market entry barriers, payer dynamics, and the economics of targeted cancer therapies.

Dr. Tzellos later worked at IQVIA in a role that continued to focus on pharmaceutical analytics. His focus has remained within oncology and pharmaceutical strategy. He currently holds a role at AstraZeneca in the UK.

While not all of his industry work is in the public domain, his academic and consulting background has shaped a clear professional profile centered on evidence-based strategy and real-world data application. Dr. Tzellos’ public writing includes personal blog posts and medium articles covering the role of science in forecasting, the rise of real-world evidence in oncology, and transitions from academic research to commercial roles.

His interests extend beyond professional analytics. Dr. Tzellos is married with two children and is an active follower of sports such as football, basketball, and Formula 1. He enjoys music, regularly attends live performances, and takes on hands-on projects around the house. These personal interests provide balance to his data-heavy professional work and illustrate the range of his day-to-day experience.

By grounding strategic insights in scientific training and verified industry contributions, Stelios Tzellos represents a model of evidence-based thinking in pharmaceutical analytics.

Ventura, California, 11 Dec 2025, ZEX PR WIRE, Dr. Matthew Longwill Ventura uses a structured form of energy medicine to help clients identify and correct the energetic blocks that often sit behind chronic symptoms. Through Be Vital Energetics, he focuses on precise energetic scanning, simple explanations, and remote sessions that address imbalance across physical, emotional, mental, and energetic layers.

Energetic imbalance can influence headaches, joint pain, back tension, sleep issues, digestive distress, and recurring discomfort that does not resolve through standard care. Dr. Longwill’s work studies the pattern behind these symptoms. He looks at how energy flow becomes disrupted and how these disruptions weaken the body’s ability to regulate and heal.

His background supports this method. Dr. Matthew Longwill holds a B.S. in Biology from Santa Clara University and a Doctor of Chiropractic from Life Chiropractic College West, magna cum laude. His training includes Nutrition Response Testing, Neuro Emotional Technique, Matrix Repatterning, Biomagnetism, and Bio Kinetics. These techniques share a focus on the body’s energetic communication network. This shared foundation shaped the development of Be Vital Energetics.

Energetic scanning follows a clear process. Dr. Longwill observes how energy moves through the field. He identifies where it slows, scatters, or becomes blocked. These patterns help explain why physical symptoms recur even when structural or biochemical findings appear normal. Once the pattern is clear, he applies targeted energetic work through remote sessions designed to restore flow and reduce interference.

Education is central to the practice. Clients learn simple testing methods they can use at home. These steps help people track their own patterns and support regulation between sessions. Dr. Matthew Longwill Ventura emphasizes clarity and direct language, so clients understand what is happening in their system and why.

Be Vital Energetics works with clients who have persistent symptoms that do not respond to conventional treatments. Many use energy medicine as a complement to their medical providers. The goal is not to replace medical care. The goal is to support the body’s natural ability to return to balance when energetic interference is cleared.

Dr. Longwill offers remote sessions only. Clients across different locations use this option for flexibility and consistent support. Many report improvements in clarity, comfort, and overall regulation after restoring flow in the energy field.

For more information, visit www.bevitalenergetics.com.

London, UK, 11 Dec 2025, ZEX PR WIRE, Stelios Tzellos, Ph.D., continues to be recognized within the pharmaceutical industry for his contributions to oncology market analysis and strategic forecasting. With a formal background in molecular biology and biochemistry from Imperial College London and multiple years of applied experience in healthcare analytics, Tzellos’ work has informed commercial planning and strategic evaluation across multiple therapeutic areas, particularly within oncology.

Dr. Tzellos earned his Bachelor’s and Master’s degrees in Biochemistry and went on to complete a Ph.D. in Molecular Biology, all from Imperial College London. His doctoral research focused on Epstein-Barr virus (EBV) gene regulation, specifically the functional differences between EBNA-2 type 1 and type 2 proteins. His findings, published in peer-reviewed journals, helped expand understanding of how EBV regulates the expression of cellular genes like CXCR7 and viral genes such as LMP-1.

His academic contributions during his Ph.D. program include co-authorship of studies examining how specific amino acid changes in EBNA-2 affect the regulation of growth-promoting genes. One study, published in the Journal of General Virology in 2014, was titled “EBV EBNA-2 type 1 and type 2 proteins induce expression of the cellular CXCR7 and EBI2 genes through a mechanism involving a common motif in their transactivation domains.” Another article, where he was the first author, expanded on the same theme of differential gene activation.

In 2014, while working as an Oncology and Haematology Analyst for GlobalData, Dr. Tzellos was quoted in a widely circulated industry report forecasting trends in Hodgkin’s lymphoma treatment. That report examined the expanding use of Adcetris and the emergence of premium-priced therapies targeting relapsed or refractory (R/R) populations. In the report, Dr. Tzellos stated:

“Adcetris currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period. Premium-priced pipeline therapies that target the R/R Hodgkin’s lymphoma population will find it easier to penetrate the market, as Adcetris has already opened the door for expensive therapeutics in this setting.”

The analysis helped contextualize the broader adoption of targeted agents and immunotherapies in hematologic malignancies and emphasized the commercial implications of label expansions and earlier-line use. Dr. Tzellos’ quote has since been referenced by healthcare publications analyzing pricing strategy and market evolution in oncology.

After his tenure at GlobalData, Dr. Tzellos joined IQVIA, where he continued to work in pharmaceutical analytics. He later moved into a commercial-facing analytics position at AstraZeneca in the UK. Across these roles, his focus has remained in strategic insight, analytics, and pharmaceutical development, particularly in oncology.

Dr. Tzellos’ professional experience intersects research, forecasting, and healthcare consulting. His work contributes to decision-making processes related to product planning, commercialization strategy, and global market evaluation. While he has not authored publicly available white papers under AstraZeneca or IQVIA, he continues to post periodically on Medium and LinkedIn about trends in pharmaceutical strategy and oncology analytics.

He resides in the United Kingdom with his wife and their two children. Outside of work, he has a range of personal interests including football, basketball, Formula 1, attending live music events, and engaging in DIY home projects.

Dr. Tzellos’ career exemplifies a transition from academic molecular biology research to high-impact pharmaceutical strategy and analytics. His ongoing work remains grounded in scientific evidence while addressing real-world commercial challenges in oncology drug development.